Is_VBZ insulin_NN an_DT endogenous_JJ cardioprotector_NN ?_SENT Abstract_NN |_SYM Stress_NP hyperglycemia_NN and_CC diabetes_NN mellitus_NN with_IN myocardial_JJ infarction_NN are_VBP associated_VBN with_IN increased_VBN risk_NN for_IN in-hospital_JJ mortality_NN ,_, congestive_JJ heart_NN failure_NN ,_, or_CC cardiogenic_JJ shock_NN ._SENT Hyperglycemia_NN triggers_VBZ free_JJ radical_JJ generation_NN and_CC suppresses_VBZ endothelial_JJ nitric_JJ oxide_NN generation_NN ,_, and_CC thus_RB initiates_VBZ and_CC perpetuates_VBZ inflammation_NN ._SENT Conversely_RB ,_, insulin_NN suppresses_VBZ production_NN of_IN tumor_NN necrosis_NN factor-alpha_NN and_CC free_JJ radicals_NNS ,_, enhances_VBZ endothelial_JJ nitric_JJ oxide_NN generation_NN ,_, and_CC improves_VBZ myocardial_JJ function_NN ._SENT It_PP is_VBZ proposed_VBN that_IN the_DT balance_NN between_IN insulin_NN and_CC plasma_NN glucose_NN levels_NNS is_VBZ critical_JJ to_TO recovery_NN and/or_CC complications_NNS that_WDT occur_VBP following_VBG acute_JJ myocardial_JJ infarction_NN and_CC in_IN the_DT critically_RB ill_JJ ._SENT Adequate_JJ attention_NN should_MD be_VB given_VBN to_TO maintaining_VBG euglycemia_NN (_( plasma_NN glucose_NN <=_NN 110_CD mg/dl_NN )_) in_IN order_NN to_TO reduce_VB infarct_NN size_NN and_CC improve_VB cardiac_JJ function_NN while_IN using_VBG a_DT glucose_NN --_: insulin_NN --_: potassium_NN cocktail_NN ._SENT cardiac_JJ failure_NN ,_, cardioprotection_NN ,_, diabetes_NN ,_, free_JJ radicals_NNS ,_, glucose_NN ,_, hyperglycemia_NN ,_, insulin_NN ,_, nitric_JJ oxide_NN ,_, tumor_NN necrosis_NN factor_NN ,_, septicemia_NN ,_, septic_JJ shock_NN ,_, Patients_NNS with_IN acute_JJ myocardial_JJ infarction_NN (_( AMI_NP )_) exhibit_NN raised_VBD blood_NN glucose_NN concentrations_NNS ._SENT In_IN addition_NN ,_, a_DT positive_JJ association_NN between_IN hyperglycemia_NN and_CC mortality_NN from_IN AMI_NP has_VBZ been_VBN reported_VBN ,_, although_IN the_DT exact_JJ reason_NN for_IN this_DT association_NN is_VBZ not_RB clear_JJ ._SENT Intensive_JJ treatment_NN with_IN insulin_NN to_TO lower_JJR plasma_NN glucose_NN concentrations_NNS decreases_VBZ overall_JJ mortality_NN in_IN patients_NNS with_IN diabetes_NN mellitus_NNS who_WP have_VBP AMI_NP ._SENT In_IN a_DT prospective_JJ ,_, randomized_VBN ,_, controlled_VBN study_NN involving_VBG adults_NNS admitted_VBN to_TO surgical_JJ intensive_JJ care_NN units_NNS and_CC receiving_VBG mechanical_JJ ventilation_NN ,_, intensive_JJ insulin_NN treatment_NN reduced_VBD mortality_NN and_CC morbidity_NN ._SENT Intensive_JJ insulin_NN treatment_NN reduced_VBD the_DT number_NN of_IN deaths_NNS from_IN multiple_JJ organ_NN failure_NN with_IN sepsis_NN ._SENT Markers_NNS of_IN inflammation_NN were_VBD found_VBN to_TO be_VB abnormal_JJ less_RBR frequently_RB in_IN the_DT intensive_JJ insulin_NN treatment_NN group_NN ._SENT This_DT suggests_VBZ that_IN hyperglycemia_NN is_VBZ harmful_JJ ,_, whereas_IN insulin_NN therapy_NN is_VBZ beneficial_JJ not_RB only_RB in_IN AMI_NP but_CC also_RB in_IN critical_JJ illness_NN with_IN or_CC without_IN diabetes_NN mellitus_NN ._SENT It_PP is_VBZ likely_JJ that_IN lack_NN of_IN insulin_NN associated_VBN with_IN hyperglycemia_NN causes_VBZ a_DT decrease_NN in_IN glycolytic_JJ substrate_NN and_CC an_DT increase_NN in_IN free_JJ fatty_JJ acids_NNS ._SENT This_DT induces_VBZ a_DT reduction_NN in_IN myocardial_JJ contractility_NN ,_, and_CC promotes_VBZ cardiac_JJ failure_NN and_CC arrhythmias_NNS ,_, leading_VBG to_TO poor_JJ outcomes_NNS in_IN such_JJ patients_NNS ._SENT inflammatory_JJ :_: Capes_NNS and_CC coworkers_NNS showed_VBD that_IN patients_NNS with_IN stress_NN hyperglycemia_NN but_CC without_IN diabetes_NN mellitus_NN at_IN the_DT time_NN of_IN AMI_NP are_VBP at_IN increased_VBN risk_NN for_IN in-hospital_JJ mortality_NN and_CC congestive_JJ heart_NN failure_NN or_CC cardiogenic_JJ shock_NN ._SENT Although_IN the_DT exact_JJ cause_NN for_IN the_DT poor_JJ prognosis_NN is_VBZ not_RB clear_JJ ,_, it_PP was_VBD suggested_VBN that_WDT hyperglycemia_NN (_( an_DT indirect_JJ reflection_NN of_IN relative_JJ insulin_NN deficiency_NN )_) increases_NNS circulating_VBG free_JJ fatty_JJ acids_NNS ,_, which_WDT are_VBP toxic_JJ to_TO myocardium_NN and_CC induce_VB arrhythmias_NNS ._SENT Hyperglycemia_NN causes_VBZ osmotic_JJ diuresis_NN ,_, and_CC the_DT resulting_VBG volume_NN depletion_NN may_MD further_RBR compromise_VB myocardial_JJ function_NN ._SENT Both_CC in_IN animal_JJ models_NNS of_IN diabetes_NN and_CC in_IN patients_NNS with_IN diabetes_NN mellitus_NN ,_, increased_VBD production_NN of_IN reactive_JJ oxygen_NN species_NNS and_CC consequent_JJ lipid_NN peroxidation_NN were_VBD noted_VBN ._SENT Hyperglycemia_NN increases_VBZ the_DT production_NN of_IN reactive_JJ oxygen_NN species_NNS inside_IN cultured_JJ aortic_JJ endothelial_JJ cells_NNS ._SENT Superoxide_NN anion_NN inactivates_VBZ both_DT endothelial_JJ nitric_JJ oxide_NN (_( NO_NP )_) and_CC prostacyclin_NN produced_VBN by_IN endothelial_JJ cells_NNS ,_, which_WDT are_VBP potent_JJ vasodilators_NNS and_CC platelet_NN antiaggregators_NNS ._SENT Thus_RB ,_, free_JJ radicals_NNS induce_VB endothelial_JJ dysfunction_NN ._SENT Normalizing_VBG levels_NNS of_IN mitochondrial_JJ reactive_JJ oxygen_NN species_NNS was_VBD reported_VBN to_TO prevent_VB glucose-induced_JJ activation_NN of_IN protein_NN kinase_NN C_NP ,_, formation_NN of_IN advanced_JJ glycation_NN end-products_NNS ,_, sorbitol_NN accumulation_NN ,_, and_CC nuclear_JJ factor-kappaB_NN (_( NF-kappaB_NP )_) activation_NN ._SENT Glucose_NN challenge_NN stimulated_VBN reactive_JJ oxygen_NN species_NN generation_NN and_CC levels_NNS of_IN p47phox_NN (_( a_DT key_JJ protein_NN of_IN the_DT enzyme_NN nicotinamide_NN adenine_NN dinucleotide_NN phosphate_NN [_SYM reduced_VBN ;_: NADPH_NP ]_SYM oxidase_NN )_) ,_, whereas_IN alpha-tocopherol_NN levels_NNS decreased_VBD significantly_RB in_IN polymorphonuclear_JJ leukocytes_NNS and_CC monocytes_NNS ,_, even_RB in_IN normal_JJ subjects_NNS ._SENT High_JJ glucose_NN concentrations_NNS induced_VBD inflammatory_JJ events_NNS in_IN rats_NNS ,_, as_RB evidenced_VBN by_IN increased_VBN leukocyte_NN rolling_NN ,_, leukocyte_NN adherence_NN ,_, leukocyte_NN transmigration_NN through_IN mesenteric_JJ venules_NNS associated_VBN with_IN attenuation_NN of_IN endothelial_JJ NO_NP release_NN ,_, and_CC increased_VBD expression_NN of_IN P-selectin_NP on_IN endotheial_JJ surfaces_NNS ._SENT Local_JJ application_NN of_IN insulin_NN attenuated_VBN these_DT proinflammatory_JJ effects_NNS ._SENT Insulin_NN infusion_NN inhibited_VBD reactive_JJ oxygen_NN species_NN generation_NN ,_, p47phox_NP and_CC NF-kappaB_NP in_IN mononuclear_JJ cells_NNS ,_, and_CC reduced_VBD soluble_JJ intercellular_JJ adhesion_NN molecule-1_NN ,_, monocyte_NN chemoattractant_NN protein-1_NN and_CC plasminogen_NN activator_NN inhibitor-1_JJ production_NN by_IN increasing_VBG NO_NP synthesis_NN ._SENT These_DT findings_NNS suggest_VBP that_IN hyperglycemia_NN has_VBZ proinflammatory_JJ whereas_IN insulin_NN exhibits_VBZ anti-inflammatory_JJ actions_NNS ._SENT The_DT exact_JJ mechanism_NN by_IN which_WDT glucose_NN stimulates_VBZ proinflammatory_JJ events_NNS is_VBZ not_RB clear_JJ ,_, although_IN indirect_JJ evidence_NN suggests_VBZ that_IN it_PP does_VBZ so_RB possibly_RB by_IN stimulating_VBG production_NN of_IN tumor_NN necrosis_NN factor_NN (TNF)-alpha_NN (_( a_DT proinflammatory_JJ cytokine_NN )_) ._SENT A_DT diet_NN with_IN a_DT high_JJ glycemic_JJ load_NN and_CC hyperglycemia_NN induced_VBD production_NN of_IN acute-phase_NN reactants_NNS ._SENT In_IN experimental_JJ animal_JJ models_NNS of_IN diabetes_NN ,_, the_DT activity_NN of_IN NADPH-dependent_JJ oxidase_NN and_CC the_DT levels_NNS of_IN NADPH_NP oxidase_NN protein_NN subunits_NN p22phox_NN ,_, p67phox_NN and_CC p47phox_NN were_VBD significantly_RB increased_VBN ,_, which_WDT accounted_VBD for_IN the_DT increased_VBN superoxide_NN production_NN in_IN addition_NN to_TO decreased_VBN endothelial_JJ NO_NP synthase_NN activity_NN ._SENT Similar_JJ to_TO glucose_NN ,_, TNF-alpha_NP also_RB enhances_VBZ free_JJ radical_JJ generation_NN by_IN augmenting_VBG polymorphonuclear_JJ leukocyte_NN NADPH_NN oxidase_NN activity_NN ,_, activates_VBZ NF-kappaB_NP ,_, and_CC increases_VBZ intercellular_JJ adhesion_NN molecule-1_JJ expression_NN in_IN endothelial_JJ cells_NNS ._SENT This_DT similarity_NN in_IN the_DT actions_NNS of_IN glucose_NN and_CC TNF-alpha_NP ,_, and_CC the_DT ability_NN of_IN former_JJ to_TO enhance_VB acute_JJ phase_NN reactants_NNS suggests_VBZ ,_, but_CC does_VBZ not_RB prove_VB ,_, that_DT glucose_NN may_MD enhance_VB TNF-alpha_NP production_NN and_CC brings_VBZ about_IN its_PP$ proinflammatory_JJ actions_NNS ._SENT alpha_NN and_CC myocardium_NN :_: TNF-alpha_NP is_VBZ secreted_VBN by_IN adipose_JJ tissue_NN ,_, macrophages_NNS and_CC cardiac_JJ tissue_NN ,_, and_CC plays_VBZ roles_NNS in_IN the_DT pathogeneses_NNS of_IN insulin_NN resistance_NN ,_, type_NN 2_CD diabetes_NN mellitus_NN ,_, inflammation_NN ,_, and_CC septic_JJ shock_NN ._SENT Release_NN of_IN TNF-alpha_NP occurs_VBZ early_RB in_IN the_DT course_NN of_IN AMI_NP and_CC reduces_VBZ myocardial_JJ contractility_NN in_IN a_DT dose-dependent_JJ manner_NN ._SENT Using_VBG anti-TNF-alpha_NN antibody_NN can_MD reduce_VB TNF-alpha-induced_JJ myocardial_JJ injury_NN and_CC dysfunction_NN ._SENT Cardiac_JJ cachexia_NN is_VBZ believed_VBN to_TO be_VB due_JJ to_TO an_DT increase_NN in_IN the_DT circulating_VBG levels_NNS of_IN TNF-alpha_NP ,_, and_CC a_DT direct_JJ correlation_NN between_IN the_DT clinical_JJ features_NNS of_IN congestive_JJ cardiac_JJ failure_NN (_( CCF_NN )_) and_CC circulating_VBG levels_NNS of_IN TNF_NP have_VBP been_VBN reported_VBN ._SENT Following_VBG cardiac_JJ transplantation_NN TNF-alpha_NP levels_NNS decrease_VBP ._SENT This_DT suggests_VBZ that_IN TNF-alpha_NP is_VBZ an_DT important_JJ mediator_NN in_IN the_DT pathogenesis_NN of_IN CCF_NN ._SENT In_IN addition_NN ,_, it_PP causes_VBZ dysfunction_NN and_CC apoptosis_NN of_IN endothelial_JJ cells_NNS ,_, and_CC enhances_VBZ generation_NN of_IN free_JJ radicals_NNS (_( including_VBG superoxide_NN anion_NN )_) ,_, which_WDT in_IN turn_NN quenches_VBZ NO_NP ._SENT Damage_NN to_TO endothelial_JJ cells_NNS triggers_VBZ procoagulant_JJ activity_NN and_CC fibrin_NN deposition_NN ._SENT These_DT events_NNS are_VBP detrimental_JJ to_TO the_DT patient_NN in_IN the_DT long_JJ run_NN ._SENT In_IN CCF_NN there_EX is_VBZ increased_VBN mesenteric_JJ venous_JJ pressure_NN ,_, which_WDT causes_VBZ intestinal_JJ edema_NN and_CC increased_VBN bowel_NN permeability_NN ._SENT This_DT causes_VBZ an_DT increase_NN in_IN endotoxin_NN absorption_NN from_IN the_DT gut_NN ._SENT Increase_NN in_IN circulating_VBG levels_NNS of_IN endotoxin_NN activates_VBZ macrophages_NNS and_CC other_JJ cells_NNS to_TO produce_VB TNF-alpha_NP ._SENT In_IN patients_NNS with_IN CCF_NN ,_, CD14_NP concentrations_NNS (_( which_WDT are_VBP indicative_JJ of_IN endotoxin-cell_NN interaction_NN )_) are_VBP raised_VBN in_IN relation_NN to_TO the_DT elevated_JJ levels_NNS of_IN TNF-alpha_NP and_CC cachexia_NN ._SENT These_DT findings_NNS suggest_VBP that_IN methods_NNS designed_VBN to_TO reduce_VB TNF-alpha_NP levels_NNS could_MD be_VB of_IN significant_JJ benefit_NN in_IN inflammation_NN ,_, septicemia_NN ,_, and_CC CCF_NN ._SENT alpha_NN and_CC insulin_NN :_: Both_CC the_DT American_NP College_NP of_IN Cardiology_NP and_CC the_DT American_NP Heart_NP Association_NP recommended_VBD that_IN intravenous_JJ glucose_NN --_: insulin_NN --_: potassium_NN (_( GIK_NP )_) be_VB given_VBN to_TO patients_NNS with_IN AMI_NP ,_, especially_RB those_DT who_WP are_VBP poor_JJ candidates_NNS for_IN thrombolytic_JJ therapy_NN and_CC in_IN whom_WP the_DT risk_NN for_IN bleeding_NN is_VBZ high_JJ ,_, because_IN the_DT GIK_NP regimen_NN was_VBD beneficial_JJ in_IN treating_VBG AMI_NP ._SENT It_PP is_VBZ generally_RB believed_VBN that_IN the_DT GIK_NP treatment_NN improves_VBZ the_DT integrity_NN and_CC function_NN of_IN myocardial_JJ cells_NNS once_IN glucose_NN and_CC potassium_NN are_VBP transported_VBN in_IN by_IN insulin_NN ._SENT Previously_RB ,_, I_PP suggested_VBD that_IN the_DT GIK_NP regimen_NN in_IN general_NN and_CC insulin_NN in_IN particular_JJ suppresses_VBZ inflammation_NN by_IN inhibiting_VBG production_NN of_IN TNF-alpha_NP ,_, macrophage_NN migration_NN inhibitory_JJ factor_NN (_( MIF_NP )_) and_CC superoxide_NN anion_NN ,_, and_CC by_IN stimulating_VBG endothelial_JJ NO_NP synthesis_NN ._SENT Satomi_NP and_CC coworkers_NNS showed_VBD that_IN exogenous_JJ insulin_NN injection_NN inhibited_VBN TNF-alpha_NP production_NN in_IN a_DT dose-related_JJ manner_NN in_IN animals_NNS after_IN lipopolysaccharide_NN challenge_NN ._SENT Addition_NN of_IN insulin_NN to_TO cultures_NNS of_IN peritoneal_JJ exudate_NN cells_NNS from_IN Propionibacterium_NN acnes_NNS primed_VBD mice_NNS blocked_VBN TNF-alpha_NP production_NN ,_, whereas_IN in_IN control_NN animals_NNS it_PP did_VBD not_RB ._SENT Fraker_NP and_CC colleagues_NNS reported_VBD that_IN reduced_VBN food_NN intake_NN ,_, decreased_VBD body_NN weight_NN gain_NN ,_, severe_JJ interstitial_JJ pneumonitis_NN ,_, periportal_JJ inflammation_NN in_IN the_DT liver_NN ,_, and_CC increases_NNS in_IN the_DT weights_NNS of_IN the_DT heart_NN ,_, lungs_NNS ,_, kidney_NN and_CC spleen_NN observed_VBN in_IN TNF-alpha-treated_JJ animals_NNS reverted_VBN to_TO normal_JJ levels_NNS when_WRB insulin_NN was_VBD administered_VBN concurrently_RB ._SENT The_DT pneumonitis_NN seen_VBN in_IN these_DT TNF-alpha-treated_JJ animals_NNS is_VBZ somewhat_RB similar_JJ to_TO the_DT adult_JJ respiratory_JJ distress_NN syndrome_NN that_WDT is_VBZ seen_VBN in_IN patients_NNS with_IN septicemia_NN and_CC septic_JJ shock_NN ,_, conditions_NNS in_IN which_WDT concentrations_NNS of_IN interleukin-1_NN ,_, TNF-alpha_NP ,_, and_CC MIF_NP are_VBP elevated_VBN ._SENT In_IN addition_NN ,_, insulin_NN suppresses_VBZ superoxide_NN anion_NN generation_NN and_CC enhances_VBZ the_DT production_NN of_IN endothelial_JJ NO_NP ._SENT Thus_RB ,_, the_DT ability_NN of_IN insulin_NN to_TO suppress_VB TNF-alpha_NP production_NN ,_, which_WDT decreases_VBZ myocardial_JJ contractility_NN ,_, could_MD be_VB one_CD mechanism_NN by_IN which_WDT the_DT GIK_NP regimen_NN is_VBZ beneficial_JJ in_IN AMI_NP ._SENT Although_IN several_JJ studies_NNS suggested_VBD that_IN GIK_NP regimen_NN preserved_VBD systolic_JJ and_CC diastolic_JJ function_NN in_IN ischemia_NN and_CC reperfusion_NN and_CC protects_VBZ the_DT myocardium_NN in_IN patients_NNS undergoing_VBG open_JJ heart_NN surgery_NN ,_, this_DT is_VBZ not_RB without_IN controversy_NN ._SENT Why_WRB did_VBD some_DT studies_NNS give_VBP positive_JJ results_NNS whereas_IN others_NNS failed_VBN to_TO show_VB a_DT benefit_NN from_IN the_DT GIK_NP regimen_NN ?_SENT On_IN closer_JJR examination_NN ,_, it_PP is_VBZ clear_JJ that_IN not_RB all_DT studies_NNS were_VBD comparable_JJ to_TO each_DT other_JJ because_IN the_DT concentrations_NNS of_IN glucose_NN and_CC insulin_NN used_VBN in_IN those_DT studies_NNS were_VBD not_RB uniform_JJ ._SENT Studies_NNS in_IN which_WDT higher_JJR concentrations_NNS of_IN insulin_NN were_VBD used_VBN showed_VBD better_JJR results_NNS than_IN did_VBD those_DT studies_NNS that_WDT employed_VBD a_DT lesser_JJR dose_NN ._SENT For_IN instance_NN ,_, studies_NNS in_IN which_WDT 33_CD %_NN glucose_NN with_IN 120_CD units_NNS of_IN insulin_NN or_CC 30_CD %_NN glucose_NN with_IN 300_CD units_NNS of_IN insulin_NN was_VBD used_VBN yielded_VBN positive_JJ results_NNS ._SENT In_IN contrast_NN ,_, the_DT results_NNS reported_VBD by_IN those_DT studies_NNS that_WDT employed_VBD a_DT lower_JJR dose_NN (_( Bruemmer-Smith_NP and_CC coworkers_NNS used_VBD 500_CD ml_NN of_IN 5_CD %_NN dextrose_NN with_IN 100_CD units_NNS of_IN insulin_NN ,_, and_CC Rao_NP and_CC colleagues_NNS supplemented_VBD the_DT cardioplegic_JJ solution_NN with_IN 10_CD units/l_NN insulin_NN )_) were_VBD less_RBR favorable_JJ ._SENT This_DT is_VBZ supported_VBN by_IN the_DT observation_NN that_IN stress_NN hyperglycemia_NN or_CC even_RB mild_JJ hyperglycemia_NN with_IN myocardial_JJ infarction_NN is_VBZ associated_VBN with_IN increased_VBN mortality_NN and_CC that_DT intensive_JJ insulin_NN treatment_NN to_TO maintain_VB blood_NN glucose_NN levels_NNS between_IN 80_CD and_CC 110_CD mg/dl_NN is_VBZ highly_RB beneficial_JJ and_CC reduces_VBZ morbidity_NN and_CC mortality_NN among_IN critically_RB ill_JJ patients_NNS ._SENT It_PP is_VBZ possible_JJ that_IN the_DT negative_JJ results_NNS obtained_VBN with_IN GIK_NP were_VBD due_JJ to_TO the_DT low_JJ dose_NN of_IN insulin_NN used_VBN ;_: this_DT invariably_RB resulted_VBN in_IN hyperglycemia_NN ,_, which_WDT is_VBZ detrimental_JJ to_TO the_DT myocardium_NN ._SENT It_PP has_VBZ been_VBN known_VBN for_IN several_JJ years_NNS that_IN continuous_JJ intravenous_JJ infusion_NN of_IN insulin_NN is_VBZ superior_JJ to_TO subcutaneous_JJ administration_NN in_IN terms_NNS of_IN glycemic_JJ control_NN ,_, especially_RB in_IN patients_NNS with_IN diabetes_NN during_IN the_DT perioperative_JJ and_CC postoperative_JJ periods_NNS ._SENT During_IN both_CC the_DT infusion_NN period_NN and_CC the_DT entire_JJ observation_NN period_NN (_( day_NN of_IN operation_NN ,_, and_CC first_JJ and_CC second_JJ postoperative_JJ days_NNS )_) ,_, GIK_NP regimen_NN resulted_VBD in_IN lower_JJR blood_NN glucose_NN levels_NNS within_IN the_DT intended_VBN range_NN of_IN 90_CD --_: 180_CD mg/dl_NN (_( 5_CD --_: 10_CD mmol/l_NN )_) as_IN compared_VBN with_IN conventional_JJ subcutaneous_JJ insulin_NN administration_NN ._SENT Improved_VBN diabetic_JJ control_NN is_VBZ believed_VBN to_TO result_VB in_IN fewer_JJR wound_NN infections_NNS and_CC better_JJR wound_NN healing_NN ._SENT However_RB ,_, this_DT view_NN may_MD be_VB too_RB simplistic_JJ ._SENT The_DT beneficial_JJ effects_NNS of_IN GIK_NP regimen_NN may_MD extend_VB beyond_IN control_NN of_IN hyperglycemia_NN alone_RB ._SENT As_RB demonstrated_VBN recently_RB ,_, GIK_NP infusion_NN may_MD salvage_VB myocardium_NN ,_, improve_VB cardiac_JJ function_NN ,_, and_CC decrease_VB mortality_NN by_IN an_DT absolute_JJ 10_CD %_NN ,_, provided_VBD that_IN hyperglycemia_NN is_VBZ prevented_VBN ._SENT There_EX is_VBZ reasonable_JJ evidence_NN to_TO suggest_VB that_IN this_DT beneficial_JJ effect_NN may_MD be_VB independent_JJ of_IN glucose_NN ._SENT These_DT results_NNS are_VBP supplemented_VBN by_IN those_DT of_IN a_DT large_JJ trial_NN conducted_VBN in_IN a_DT heterogeneous_JJ group_NN of_IN 1548_CD critically_RB ill_JJ patients_NNS ._SENT In_IN that_DT trial_NN ,_, intensive_JJ insulin_NN therapy_NN to_TO avoid_VB hyperglycemia_NN (_( blood_NN glucose_NN was_VBD maintained_VBN below_IN 110_CD mg/dl_NN )_) in_IN predominantly_RB nondiabetic_JJ patients_NNS led_VBN to_TO a_DT decrease_NN in_IN morbidity_NN and_CC mortality_NN as_IN compared_VBN with_IN less_RBR intensively_RB treated_VBN patients_NNS (_( blood_NN glucose_NN maintained_VBN between_IN 180_CD and_CC 200_CD mg/dl_NN )_) ._SENT Those_DT findings_NNS suggest_VBP that_IN maintaining_VBG blood_NN glucose_NN concentrations_NNS at_IN 110_CD mg/dl_NN or_CC less_JJR is_VBZ critical_JJ in_IN obtaining_VBG the_DT benefits_NNS of_IN insulin_NN administration_NN ._SENT This_DT is_VBZ supported_VBN by_IN the_DT observation_NN that_IN cardiac_JJ dysfunction_NN induced_VBN by_IN endotoxin_NN administration_NN was_VBD not_RB related_VBN to_TO arterial_JJ blood_NN glucose_NN concentrations_NNS ._SENT Furthermore_RB ,_, infusions_NNS of_IN insulin_NN reversed_VBD cardiac_JJ failure_NN and_CC maintained_VBD normal_JJ performance_NN in_IN spite_NN of_IN wide_JJ ranges_NNS in_IN glucose_NN concentrations_NNS (_( 5_CD --_: 120_CD mg/dl_NN )_) ,_, suggesting_VBG that_IN myocardial_JJ dysfunction_NN is_VBZ not_RB precipitated_VBN or_CC induced_VBN by_IN the_DT hypoglycemia_NN of_IN endotoxin_NN shock_NN ._SENT The_DT ability_NN of_IN insulin_NN to_TO improve_VB myocardial_JJ performance_NN may_MD be_VB related_VBN to_TO its_PP$ capacity_NN to_TO suppress_VB TNF-alpha_NP ,_, MIF_NP ,_, and_CC superoxide_NN anion_NN generation_NN ._SENT Therapeutic_JJ administration_NN of_IN high_JJ doses_NNS of_IN insulin_NN results_NNS in_IN an_DT accumulation_NN of_IN myocardial_JJ glycogen_NN stores_NNS and_CC improvement_NN in_IN glucose_NN utilization_NN ._SENT This_DT leads_VBZ to_TO augmented_JJ myocardial_JJ adenosine_NN triphosphate_NN provision_NN and_CC maintains_VBZ cellular_JJ energy_NN charge_NN during_IN coronary_JJ ischemia_NN ,_, resulting_VBG in_IN better_JJR tolerance_NN to_TO ischemia_NN and_CC improved_VBN myocardial_JJ protection_NN ._SENT It_PP is_VBZ evident_JJ from_IN the_DT preceding_JJ discussion_NN that_IN hyperglycemia_NN is_VBZ harmful_JJ whereas_IN insulin_NN treatment_NN is_VBZ beneficial_JJ ._SENT Even_RB mild_JJ hyperglycemia_NN is_VBZ associated_VBN with_IN poor_JJ neurologic_JJ outcome_NN after_IN brain_NN injury_NN and_CC stroke_NN ,_, and_CC burns_NNS or_CC surgery_NN in_IN humans_NNS ._SENT Animal_NN studies_NNS revealed_VBD that_IN hyperglycemia_NN aggravates_VBZ endotoxin_NN shock_NN and_CC that_DT insulin_NN treatment_NN decreases_VBZ mortality_NN ._SENT What_WP are_VBP the_DT potential_JJ mechanisms_NNS by_IN which_WDT insulin_NN is_VBZ able_JJ to_TO bring_VB about_IN its_PP$ beneficial_JJ actions_NNS ?_SENT Apart_RB from_IN its_PP$ ability_NN to_TO lower_JJR blood_NN glucose_NN and_CC to_TO inhibit_VB production_NN of_IN potentially_RB dangerous_JJ proinflammatory_JJ cytokines_NNS (_( i.e._FW TNF-alpha_NP ,_, MIF_NP ,_, and_CC superoxide_NN anion_NN )_) ,_, insulin_NN has_VBZ the_DT following_VBG actions_NNS :_: it_PP stimulates_VBZ glucose_NN uptake/glycolysis_NN ,_, pyruvate_JJ dehydrogenase_NN and_CC energy_NN production_NN ;_: it_PP increases_VBZ muscle_NN protein_NN synthesis_NN ;_: it_PP inhibits_VBZ apoptosis_NN and_CC improves_VBZ repair_NN of_IN damaged_JJ tissues_NNS ;_: it_PP promotes_VBZ ischemic_JJ preconditioning_VBG and_CC lessens_VBZ ischemia/reperfusion_NN damage_NN (_( for_IN review_NN )_) ;_: and_CC it_PP exhibits_VBZ anti-inflammatory_JJ actions_NNS ._SENT Because_IN hyperglycemia_NN induces_VBZ apoptosis_NN of_IN myocardial_JJ cells_NNS ,_, strict_JJ control_NN of_IN blood_NN glucose_NN is_VBZ essential_JJ to_TO preserve_VB cardiac_JJ function_NN both_CC in_IN diabetic_JJ and_CC nondiabetic_JJ persons_NNS with_IN stress_NN hyperglycemia_NN ._SENT The_DT ability_NN of_IN insulin_NN to_TO enhance_VB endothelial_JJ NO_NP synthesis_NN is_VBZ particularly_RB significant_JJ when_WRB one_PP considers_VBZ its_PP$ beneficial_JJ action_NN in_IN AMI_NP ,_, stroke_NN ,_, and_CC critical_JJ illness_NN ._SENT Recent_JJ studies_NNS suggested_VBD that_DT administration_NN of_IN L-arginine_NP (_( the_DT precursor_NN of_IN NO_NP )_) improves_VBZ postischemic_JJ recovery_NN of_IN endothelial_JJ and_CC vascular_JJ smooth_JJ muscle_NN functions_NNS after_IN cold_JJ cardioplegic_JJ arrest_NN ,_, and_CC enhances_VBZ cardioprotection_NN and_CC postischemic_JJ functional_JJ recovery_NN and_CC reduces_VBZ infarct_NN size_NN of_IN the_DT myocardium_NN ._SENT Hence_RB ,_, some_DT of_IN the_DT beneficial_JJ actions_NNS of_IN insulin_NN (_( and_CC therefore_RB those_DT of_IN the_DT GIK_NP regimen_NN )_) in_IN various_JJ conditions_NNS could_MD be_VB attributable_JJ to_TO an_DT increase_NN in_IN endothelial_JJ NO_NP synthesis_NN ._SENT In_IN summary_NN ,_, GIK_NP regimen_NN is_VBZ useful_JJ in_IN preserving_VBG the_DT myocardium_NN in_IN septicemia_NN and_CC septic_JJ shock_NN ,_, and_CC in_IN patients_NNS with_IN severe_JJ burn_NN injury_NN ,_, provided_VBD that_IN blood_NN glucose_NN levels_NNS are_VBP maintained_VBN at_IN 110_CD mg/dl_NN or_CC below_RB by_IN employing_VBG an_DT adequate_JJ insulin_NN dose_NN ._SENT Thus_RB ,_, insulin_NN when_WRB present_JJ in_IN appropriate_JJ amounts_NNS preserves_VBZ myocardial_JJ integrity_NN and_CC function_NN ._SENT None_NN declared_VBD ._SENT AMI_NN =_SYM acute_JJ myocardial_JJ infarction_NN ;_: CCF_NN =_SYM congestive_JJ cardiac_JJ failure_NN ;_: GIK_NP =_SYM glucose-insulin-potassium_NN ;_: MIF_NP =_SYM macrophage_NN migration_NN inhibitory_JJ factor_NN ;_: NADPH_NP =_SYM nicotinamide_NN adenine_NN dinucleotide_NN phosphate_NN (_( reduced_VBN )_) ;_: NF-kappaB_NP =_SYM nuclear_JJ factor-kappaB_NN ;_: NO_NP =_SYM nitric_JJ oxide_NN ;_: TNF_NP =_SYM tumor_NN necrosis_NN factor_NN ._SENT 